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parasite expressing histidine‑rich protein II
Kristin E. Poti1,2, Amanda E. Balaban1,2, Priya Pal3,4, Tamaki Kobayashi2,5, Daniel E. Goldberg3,4, Photini Sinnis1,2
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Abstract
Background: The Plasmodium falciparum histidine-rich protein II (PfHRP2) is a common biomarker used in malaria
rapid diagnostic tests (RDTs), but can persist in the blood for up to 40 days following curative treatment. The persistence of PfHRP2 presents a false positive limitation to diagnostic interpretation. However, the in vivo dynamics and
compartmentalization underlying PfHRP2 persistence have not been fully characterized in the plasma and erythrocyte (RBC) fraction of the whole blood.
Methods: The kinetics and persistence of PfHRP2 in the plasma and RBC fractions of the whole blood were investigated post-treatment in human clinical samples and samples isolated from BALB/c mice infected with a novel transgenic Plasmodium berghei parasite engineered to express PfHRP2 (PbPfHRP2).
Results: PfHRP2 levels in human RBCs were consistently 20–40 times greater than plasma levels, even post-parasite
clearance. PfHRP2 positive, DNA negative, once-infected RBCs were identified in patients that comprised 0.1–1%
of total RBCs for 6 and 12 days post-treatment, even post-atovaquone–proguanil regimens. Transgenic PbPfHRP2
parasites in BALB/c mice produced and exported tgPfHRP2 to the RBC cytosol similar to P. falciparum. As in humans,
tgPfHRP2 levels were found to be approximately 20-fold higher within the RBC fraction than the plasma post-treatment. RBC localized tgPfHRP2 persisted longer than tgPfHRP2 in the plasma after curative treatment. tgPfHRP2 positive, but DNA negative once-infected RBCs were also detected in mouse peripheral blood for 7–9 days after curative
treatment.
Conclusions: The data suggest that persistence of PfHRP2 is due to slower clearance of protein from the RBC fraction
of the whole blood. This appears to be a result of the presence PfHRP2 in previously infected, pitted cells, as opposed
to PfHRP2 binding naïve RBCs in circulation post-treatment. The results thus confirm that the extended duration of
RDT positivity after parasite clearance is likely due to pitted, once-infected RBCs that remain positive for PfHRP2.
Keywords: Malaria, Histidine-rich protein II, HRP2, Persistence, Once-infected RBCs, Erythrocyte pitting, Plasmodium
berghei, Rapid diagnostic test
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Background
As of 2017, there were over 200 million malaria cases and
435,000 deaths [1]. Greater than 90% of these malaria
infections were caused by the Plasmodium falciparum
parasite predominately in Africa, which causes the most
severe disease in humans [1]. In Africa, most malaria
rapid diagnostic tests (RDT) detect the abundant P. falciparum protein, histidine-rich protein II (PfHRP2)
[2–4]. Other RDTs detect aldolase or lactate dehydrogenase either alone or in combination. At parasite densities
greater than 500–1000 parasites/µL of whole blood, the
RDT has demonstrated high sensitivity and specificity,
similar to the microscopy standard [3–6]. Additionally,
the low cost, minimal resources required, rapid results,
and ease of use, has led the World Health Organization
to recommend the RDT for diagnosing malaria prior to
treatment in the field [7].
Despite the use of PfHRP2 as the antigen in the RDT,
PfHRP2 compartmental kinetics in the two blood fractions during infection and during parasite clearance posttreatment have not been extensively characterized. In
particular, the dynamics of PfHRP2 in the RBC fraction
of the whole blood has not been specifically measured.
To date, the half-life of PfHRP2 has been estimated to be
3.67 days in plasma and 3–5 days in the whole blood following treatment [8, 9]. Ndour et al. also demonstrated
that overall PfHRP2 levels in whole blood treatment
decreased at a slower rate compared to PfHRP2 plasma
levels when compared only on day 0 and 3 post-treatment [10]. However, no estimations were specifically
determined for PfHRP2 clearance time from the RBC
fraction of the whole blood after treatment for comparison, nor were these kinetic parameters in the two different blood fractions (plasma vs. RBCs) compared to
the clearance time of parasite genomic DNA. Additionally, PfHRP2 demonstrates a unique biologic persistence
in patients regardless of successful treatment with antimalarials, indicating that PfHRP2 clears from the blood
slower than parasites [10–13]. In fact, PfHRP2 can persist
at low, detectable levels for several weeks after treatment
[10–13], presenting a challenge for RDT interpretation
as a result of false positive interpretations of test results,
especially when utilizing these tests in malaria endemic
regions or to measure treatment response and assess
treatment failure [14].
Plasmodium falciparum is the only human Plasmodium species that produces PfHRP2 with expression
throughout the asexual intraerythrocytic cycle and early
stages of gametocytogenesis [15–21]. Each parasite produces approximately 2–10 femtograms of PfHRP2 per
48 h replication cycle [20, 21], but only 3% of PfHRP2
produced is retained by the parasite, localizing to the parasite cytoplasm or food vacuole [22, 23]. The remaining
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97% is exported into the infected RBC (iRBC) cytoplasm,
concentrating in packets near the iRBC membrane [16,
22]. PfHRP2 can also be secreted from intact iRBCs, but
the majority (> 90%) is released when mature schizonts
rupture the iRBC to release merozoites [16, 19]. Following release, PfHRP2 can be detected in various bodily fluids including whole blood, RBCs, plasma, serum, urine,
cerebral spinal fluid, and saliva [16, 19, 24–27]. However,
the physiological function of PfHRP2 and the significance
of its localization are unknown. Experimental evidence
indicates PfHRP2 can promote coagulation [28], interfere
with immune cell activation [29], and may contribute to
cerebral malaria pathology by disrupting barrier integrity
in the brain [30].
To probe PfHRP2 kinetics in vivo, human whole blood
samples were fractionated into their component parts of
plasma and washed RBCs for PfHRP2 quantification and
immunofluorescence analysis. A novel transgenic Plasmodium berghei mouse parasite was also engineered to
express the PfHRP2 protein (PbPfHRP2) for an additional
in vivo model for further correlative studies of PfHRP2
kinetics.

Methods
Plasmodium falciparum patient blood collection

De-identified, human whole blood samples isolated from
patients with a P. falciparum infection were collected
from the Johns Hopkins Hospital Microbiology Lab.
DNA was extracted from 20 µL of whole blood using
the QIAamp DNA Blood Mini Kit and eluted in 50 µL
of water for qPCR amplification, as described previously
[31], using novel oligonucleotide primers and a fluorescent probe specific for the P. falciparum Pfs25 gene
(Additional file 1: Table S1). The remaining blood was
centrifuged at 5000×g for 4.5 min to separate plasma and
RBC fractions. The RBCs were washed four times with
1 mL of PBS.
Recombinant and native PfHRP2 protein purification

The PfHRP2 gene, inserted into the pET 15b vector
and cloned into Escherichia coli BL 21/DE3 cells, was
expressed and purified using a previously described protocol [23]. Native PfHRP2 protein was purified using
the same protocol from pelleted RBCs cultured with the
P. falciparum FCQ79 parasite strain provided by PATH
[23]. Concentrations of purified proteins were determined using amino acid analysis completed by the Protein Structure Core at the University of Nebraska.
Construction of transgenic PbPfHRP2 parasite

The
full-length
P.
falciparum
3D7
HRP2
(PF3D7_0831800) gene was inserted into the pL1694 vector and expressed under the P. berghei HSP70 promoter,
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with a 2A skip peptide between PfHRP2 and GFP. The
cassette was flanked with integration sites for the 230p
gene in P. berghei. Second passage P. berghei (strain
ANKA) parasites were purified from 5 mice at 1% parasitaemia by collecting blood via cardiac puncture. Purified, mature schizonts (5 × 107) were generated in vitro
and transfected with 10 µg of pL1694 + HRPII-2A-GFP
linearized with Bcl1 and Sap1, as previously described
[32, 33]. Transfected parasites were injected into the
tail vein of 6–8-week-old female Swiss Webster mice
(Taconic). Utilizing the human dihydrofolate reductase
(DHFR) selection cassette, progeny were selected with
pyrimethamine at 7 mg/mL in the drinking water. Blood
was collected via cardiac puncture and single clones of
transfected parasites were generated by diluting parasites at 1 parasite/mouse across 20 mice. Isolated clones
were screened by PCR for correct genetic manipulation
(Additional file 2). PfHRP2 protein expression in vivo was
verified by RDT, western blot, and immunofluorescence
microscopy (Fig. 3).
In vivo murine model for measuring transgenic PfHRP2
kinetics

Eleven 8-week-old female BALB/c mice (Jackson Laboratory) were infected with approximately 500,000 to
1,000,000 PbPfHRP2 iRBCs isolated from a donor mouse.
Once mice reached > 5% parasitaemia at days 4–5 postinfection, they were administered, via intraperitoneal
injection, 3 doses of 50 mg/kg of artesunate at 0, 8, and
24 h and a single dose of 36 mg/kg of pyronaridine at
24 h. Artesunate (Sigma-Aldrich) was dissolved in 5%
NaHCO3 and pyronaridine tetraphosphate (SigmaAldrich) was dissolved in nuclease-free water. Parasite clearance time was monitored by blood films and
qPCR performed as previously described [31] on DNA
extracted from 20 µL of whole blood, using primers and
probes specific for P. berghei ANKA 18S rRNA (Additional file 1: Table S1). Three copies of 18S rRNA/parasite was assumed to calculate parasites/µL because the
primers and probes are capable of binding 3 copies of the
P. berghei 18S rRNA gene on chromosomes 5, 7 and 12,
as was determined by BLASTing the sequences of these
primers and probes against the P. berghei ANKA genome
using PlasmoDB v.41. In the P. berghei genome, there are
four ribosomal units, classified into two types, A-type
(includes units A and B) and S-type (includes units C and
D) [34], and three of these four units have been shown to
have greater than 90% sequence homology (A, C, and D)
[34–36]. 140 µL of tail blood was drawn daily for protein
quantification. Drawing this volume of blood daily did
not impact protein kinetics or clearance, as blood drawn
only prior to treatment (day 0) and on day 5 or 7 posttreatment yielded similar PfHRP2 kinetics.
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The blood was centrifuged at 5000×g for 4.5 min to
separate plasma and RBC fractions. The RBCs were
washed four times with 1 mL of PBS. The same methods
were used for the splenic and asplenic mouse experiments. Female BALB/c mice (n = 5) were splenectomized
by a Johns Hopkins veterinarian at 7 weeks of age,
2 weeks prior to infection.
Immunofluorescence microscopy

Slides were fixed and permeabilized in methanol at
− 20 °C for 20 min and stored at − 80 °C. Prior to staining, slides were blocked for 1 h at room temperature
with 1% bovine serum albumin (BSA)/PBS. Slides were
washed with PBS and incubated for 1 h with mouse antiPfHRP2 antibody 3A4 (1 mg/mL) conjugated to Alexa
Fluor-594 diluted 1:200 in 1% BSA/PBS. After washing,
slides were incubated with a rabbit anti-Plasmodium
enolase antibody diluted 1:50 in 1% BSA/PBS. Slides
were washed and incubated for 1 h with Alexa Fluor488 labeled goat anti-rabbit IgG (Invitrogen), diluted
1:500 in 1% BSA/PBS. Slides were washed and briefly
dried. ProLong Gold antifade reagent with DAPI (ThermoFisher) was added to the wells and sealed under a
coverslip. Images were captured with the Zeiss AxioImager M2 microscope equipped with a Hamamatsu Orca
R2 camera. Deconvolution and image analysis were done
using the Velocity Imaging Software. Approximately 1500
RBCs were counted for each human patient (n = 6) to
determine the percentage of PfHRP2 positive, DAPI negative, once-infected RBCs.
PfHRP2 enzyme‑linked immunosorbent assay (ELISA)

The Malaria Ag CELISA specific for PfHRP2 used to
quantify PfHRP2 in murine and patient samples was performed according to the manufacturer’s instructions [37].
Absorbance was read at 450 nm using the BMG Labtech
POLARstar OPTIMA plate reader. The limit of detection (LOD) was determined on each plate by averaging
the absorbance of the negative controls for each blood
fraction and adding 3 standard deviations to the mean.
Any absorbance reading under the LOD was defined as
PfHRP2 negative. The limit of quantitation (LOQ) was
determined by the linear range of the standard curve
on each plate. The LOQ was approximately 2 ng/mL of
PfHRP2.
PfHRP2 RBC binding assay

Plasma isolated from P. falciparum-infected patients
(n = 5) at a concentration of 1000–3000 ng/mL of
PfHRP2, and human serum spiked with a very high concentration of rPfHPR2 well above circulating plasma
levels observed during severe infection, or a lower concentration of PfHRP2, were added to uninfected, human
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 + erythrocytes to reconstitute whole blood at a 40%
O
haematocrit. Additionally, 200 µL of tail blood was drawn
from naïve BALB/c mice and deposited in 20 µL of 1 mg/
mL heparin in PBS. Blood was centrifuged at 5000×g
for 4.5 min to isolate plasma. The RBCs were washed
one time with 1 mL of PBS. The mouse plasma was then
spiked with the same concentrations of rPfHRP2 and
added to the washed RBCs to reconstitute whole blood
at 40% haematocrit. Plasma/sera samples containing no
PfHRP2 protein were used as controls. All were incubated at 37 °C for at least 12 h. After incubation, samples
were centrifuged to separate plasma from RBCs. RBCs
were subsequently washed 4 times with 1 mL of PBS.
Three individual replicates were performed.
In vivo model for measuring recombinant PfHPR2 plasma
kinetics

Naïve, 8-week old female BALB/c mice received an intraperitoneal injection of 20 µg of recombinant PfHRP2
(rPfHRP2) in 200 µL of PBS. Tail blood (50 or 100 µL)
was deposited in 1 mg/mL heparin in PBS to prevent
clotting. Blood was centrifuged at 5000×g for 4.5 min to
isolate plasma. The remaining RBCs were washed two
times with 1 mL of PBS.
Data analysis

The majority of data was analysed using GraphPad Prism
(v.5). Data are graphed as mean ± SEM. PfHRP2 levels in
the RBCs and plasma were extrapolated using a standard

curve and linear regression analysis. Protein half-life was
determined using a first-order decay equation. For the
comparison between splenic and asplenic mice, data were
normalized to percent of total remaining. The statistical methods used include: the Wilcoxon signed-rank test
or Mann–Whitney U test to measure differences in the
means of two matched or unmatched groups, first-order
decay analysis to calculate half-life, log-rank survival
analysis to compare clearance times, and a randomeffects GLS regression model for analysing associations
between tgPfHRP2 in the plasma and RBC fractions of
splenic or asplenic mice. The random-effects GLS regression was used to account and adjust for within-subject
correlation, using random intercept and robust standard
errors. This analysis was performed with Stata version 14
(StataCorp LP, College Station, USA).

Results
Persistence of PfHRP2 within human RBCs

The persistence of PfHRP2 in whole blood has been documented [10–13], but has not been extensively characterized in the blood’s individual compartments, the plasma
and the RBCs. We obtained whole blood from 6 patients
diagnosed with P. falciparum malaria at the hospital laboratory with parasitaemias ranging from < 0.5 to 12%, as
measured by microscopy (Table 1). The whole blood was
fractionated into plasma and washed RBCs for a quantitative, compartmental analysis of PfHRP2 by ELISA before
and after treatment with anti-malarial combinations of

Table 1 Quantification of RBCs positive for PfHRP2 but parasite negative in patients post-treatment for P. falciparum
Pt

Days posttreatment

Pfs25 copies/µL

RBC
PfHRP2
(ng/mL)

Plasma
PfHRP2 RBC/
PfHRP2 (ng/ Plasma ratio
mL)

% of iRBCs/ % of PfHRP2
total RBCs positive/total
RBCs

Treatment

1

1

482,693

183,208

7116

26

11.6

Not done

2

2759

160,177

2289

70

< 0.5

3.7

Doxycycline, quinidine,
artemether–lumefantrine

2.4

502

74,179

2272

33

0

5.2

3

150

79,094

1214

65

0

6.5

0

25,830

397

65

0

3.5

1

11,945

37,948

1999

19

1.2

Not done

3

516

4535

92

49

< 0.5

0.38

0

50,398

43,787

2113

21

2.8

0

1

498

16,370

1529

11

0

1.2

0

0.63

1.0

Not done

0

1.7

< 0.5

Not done

1.1

Not done

12
2
3

4
5

6

2

158

8821

847

10

1

14,289

21,140

85

248

6

0

43

21

2

0

24

277

11

25

1

12,863

38,051

3

12,683

3

101

2759

129

21

0

0

2

3141

12,372

181

68

< 0.5

0.13

Pt patient

Atovaquone–proguanil
Artemether–lumefantrine

Quinine, atovaquone–proguanil
Atovaquone–proguanil

Atovaquone–proguanil
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artemether–lumefantrine (n = 2) or atovaquone–proguanil (n = 4) (Table 1; Fig. 1a, b). The initial ratio of RBC to
plasma levels of PfHRP2 prior to treatment approximated
20-fold and this ratio tended to increase to 40-fold or
greater following treatment with both anti-malarial regimens (Table 1; Fig. 1c). PfHRP2 levels in the RBC fraction only declined three-to tenfold in the days following
either treatment regimen, while genomic copies of the P.
falciparum Pfs25 gene decreased 20- to 100-fold (Table 1;
Fig. 1a, b). All iRBCs cleared from the peripheral blood
within 2–3 days post-treatment when measured by
microscopy, despite parasite genomic DNA remaining
detectable when measured by qPCR (Table 1). To identify

Page 5 of 15

the source of PfHRP2 in the blood post-parasite clearance, we performed immunofluorescence microscopy
on RBCs with an antibody specific for PfHRP2 and DAPI
staining to identify parasites. Remarkably, we observed
PfHRP2 positive, but DNA negative, RBCs at approximately 0.1–1% of total RBCs post-treatment, specifically
from days 1 to 3 and day 12 post-treatment (Table 1;
Fig. 2; Additional file 3). This indicated the presence of
what was likely once-infected RBCs, in which the parasite
was cleared, but PfHRP2 remains within the cytoplasm of
the RBC. The phenomenon was observed after treatment
with both artemether–lumefantrine and atovaquone–
proguanil in the small number of patients we examined
(Table 1; Fig. 2). Also, in the 6 patients tested, no onceinfected RBCs were observed pre-treatment (Additional
file 4).
Transgenic PbPfHRP2 parasites synthesize and export
the PfHRP2 protein

Fig. 1 Kinetics of PfHRP2 following P. falciparum infection. a, b
Blood was drawn from patients and fractionated into plasma and
RBCs. Parasite genomic DNA clearance in a representative single
patient post-treatment with artemether–lumefantrine (a, left) or
atovaquone–proguanil (b, left) was quantified using TaqMan primers
and probes specific for P. falciparum Pfs25. PfHRP2 protein levels were
quantified in the plasma and RBCs post-treatment with artemether–
lumefantrine (a, right) and atovaquone–proguanil (b, right) by ELISA.
c The ratio of PfHRP2 concentration in the RBCs to plasma in each
patient (n = 6) was calculated over the days post-treatment. Data are
represented as mean ± SEM

In order to fine tune the dynamics of PfHRP2 in vivo, a
controlled experimental model was utilized in which a
P. berghei rodent parasite (PbPfHRP2), which lacks the
PfHRP2 gene family, was engineered to express PfHRP2
(tgPfHRP2) (Additional file 2). Expression and localization of the transgenic PfHRP2 protein (tgPfHRP2) was
validated in the novel mouse model by western blot
and immunofluorescence (Fig. 3). The presence of tgPfHRP2 in the whole blood of BALB/c mice was detected
using a BinaxNOW Malaria Rapid Diagnostic Test™
that qualitatively detects PfHRP2 and pan-species aldolase (Fig. 3a). Western blot analysis confirmed the presence of tgPfHRP2 in the iRBCs (Fig. 3b). tgPfHRP2 was
detected in the RBC cytosolic fraction after saponin lysis
(Fig. 3b), suggesting it was exported into the iRBC cytoplasm. Immunofluorescence microscopy on PbPfHRP2
iRBCs was performed using monoclonal antibodies
against PfHRP2 and Plasmodium enolase, a known parasite-localized protein, to differentiate the parasite from
the iRBC cytoplasm. In this assay, tgPfHRP2 localized to
both the parasite and iRBC cytoplasm (Fig. 3c). Importantly, the PfHRP2 staining observed in PbPfHRP2 iRBCs
mimicked the staining of P. falciparum iRBCs (Fig. 3c).
PfHRP2 was not detected in negative controls, including
RBCs infected with the P. berghei ANKA wild-type strain
that does not express PfHRP2 and uninfected RBCs
(Fig. 3b, c).
Investigating kinetics of tgPfHRP2 during infection
with PbPfHRP2

BALB/c mice were infected with PbPfHRP2 and 5 days
post-infection, reached an average parasitaemia of 10.5%,
as measured by microscopy, or 675,283 parasites/µL
quantified by qPCR (Fig. 4a). On day 5 post-infection,
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Fig. 2 Presence of once-infected RBCs post-treatment with different anti-malarials. Once-infected RBCs were detected in patients on day 3
post-treatment with either artemether–lumefantrine (left) or atovaquone–proguanil (right). Once-infected RBCs were defined as cells with positive
PfHRP2 staining (red) but no DAPI staining (blue)

mice were treated with three doses of 50 mg/kg of artesunate (0–8–24 h post-initial treatment) and 36 mg/kg of
pyronaridine (24 h post-initial treatment) to cure mice
of parasites (Fig. 4a). At this peak parasitaemia prior to
treatment, the average concentrations of tgPfHP2 in the

plasma and RBCs were 12,512 ng/mL and 179,433 ng/
mL, respectively (Fig. 4a, b). tgPfHRP2 levels were significantly higher in the RBC fraction (10–20 fold) compared
to the plasma over the days post-treatment (p ≤ 0.0001,
random-effects GLS regression model) (Fig. 4b, c). The
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Fig. 3 Characterization of the synthesis and localization of PfHRP2 by transgenic PbPfHRP2 parasite. a BinaxNOW Malaria RDT™ detecting tgPfHRP2
and Plasmodium aldolase in the whole blood of a PbPfHRP2 infected mouse. b tgPfHRP2 was detected in iRBCs, and exported to the iRBC cytoplasm
(Saponin, SN). RBCs were lysed with saponin to isolate their cytoplasmic fraction. Purified recombinant and native PfHRP2 protein were run as
controls. c tgPfHRP2 (red) localized within the parasite, demarcated by Plasmodium enolase staining (green), and the RBC cytosol, similar to what
was observed in P. falciparum iRBCs. An uninfected mouse RBC and a P. berghei ANKA iRBC that does not produce PfHRP2 are shown as controls

half-life of tgPfHRP2 following treatment was calculated
for each blood fraction using a first-order decay equation.
While not significantly different, tgPfHRP2 had a slightly
longer half-life in the RBCs at 13.1 h (median R2 = 0.989)
compared to 10.2 h in the plasma (median R2 = 0.999)
(p = 0.27, Wilcoxon signed-rank test) (Fig. 4d).
Determining tgPfHRP2 persistence duration in the plasma
and RBCs compared to microscopy and PCR

Median parasite clearance time measured by microscopy
was 3 days post-treatment (Fig. 5a). However, the median
parasite genomic DNA clearance time quantified by
qPCR was significantly longer at 7 days (p ≤ 0.0001, logrank) (Fig. 5a). Median plasma tgPfHRP2 clearance time
was 5 days while RBC clearance was significantly longer
at 9 days (p ≤ 0.0001, log-rank) (Fig. 5b). Consequently,
tgPfHRP2 positivity in the different blood fractions,

particularly within the RBC fraction, outlasted detectable
parasites by microscopy (Fig. 5a, b). Parasite genomic
DNA was detected by qPCR longer than plasma tgPfHRP2, but protein in the RBCs persisted at least 1-day
post genomic DNA clearance (Fig. 5a, b). tgPfHRP2
clearance time from the RBCs measured by ELISA correlated with its clearance time from whole blood of
8–9 days measured by RDT (Fig. 5c). RDT analysis also
demonstrated that the Plasmodium aldolase protein was
eliminated from the whole blood on day 4 post-treatment, shortly after parasites were no longer detected in
peripheral blood (Fig. 5c).
Identifying once‑infected, tgPfHRP2 positive murine RBCs
post‑treatment

The source of tgPfHRP2 in RBCs after parasite clearance
was hypothesized to be once-infected RBCs, positive
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Fig. 4 Kinetics of tgPfHRP2 following PbPfHRP2 infection. Tail blood was extracted daily from PbPfHRP2 infected female BALB/c mice
post-treatment with artesunate and pyronaridine administered for cure (n = 11). Blood was fractionated into plasma and RBCs. a Parasite genomic
DNA clearance post-treatment was quantified using qPCR, with TaqMan primers and probes specific for P. berghei ANKA 18S rRNA. Data are
represented as mean ± SEM. b tgPfHRP2 protein levels post-treatment were quantified in the two blood fractions by ELISA. Data are represented as
mean ± SEM. c The ratio of tgPfHRP2 concentration in the RBCs to plasma in each mouse was calculated over the first 4 days post-treatment. Data
are represented as mean ± SEM. d The half-life of the tgPfHRP2 was quantified in the plasma and washed RBCs using a first-order decay equation
model constrained at a plateau of Y = 0. Each point represents an individual mouse with mean ± SEM displayed. Data were analysed using a
Wilcoxon signed-rank test

for PfHRP2 but parasite negative, as were observed in
human patients post-treatment (Fig. 2). Immunofluorescence microscopy on mouse RBCs was performed
with an antibody specific for PfHRP2 and DAPI staining
to identify parasites. tgPfHRP2 was detected in iRBCs
(DAPI positive) isolated pre-treatment as well as in
RBCs isolated 2, 3, and 4 days post-treatment that were
DAPI negative (Fig. 6a). This indicates the presence of
once-infected RBCs positive for PfHRP2 in their cytoplasm in our mouse model. Importantly, PfHRP2 was
not detected in naive mouse or human RBCs, indicating
specific recognition of parasite derived PfHRP2 (Fig. 6).
PfHRP2-positive, parasite-negative, once-infected RBCs
that were observed in a human patient on days 2, 3 and
12 post-treatment with artemether–lumefantrine for a P.

falciparum infection with an 11.6% initial parasitaemia
(Fig. 6b), were morphologically similar to those identified
in the mouse model (Fig. 6).
Investigating potential binding of PfHRP2 to uninfected,
naïve RBCs

Slower clearance of PfHRP2 from the RBC fraction in
humans and mice could be the result of plasma PfHRP2
binding to naïve RBCs in circulation. To investigate binding, partitioning of PfHRP2 was measured between naïve
RBCs and plasma isolated from P. falciparum infected
patients or human serum/mouse plasma spiked with
recombinant PfHRP2 at average levels > 100,000 ng/
mL or < 30,000 ng/mL as measured by ELISA, that were
incubated together in vitro (Additional file 5: Table S2).
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Fig. 5 Clearance times of PbPfHRP2 parasites and tgPfHRP2 protein. Female BALB/c mice infected with the PbPfHRP2 parasite (n = 11) were
administered artesunate and pyronaridine to cure. a Parasite clearance and cure were determined by daily Giemsa-stained blood films and qPCR
performed on DNA extracted from whole blood, using TaqMan primers and probes specific for P. berghei ANKA 18S rRNA. b Blood extracted from
each infected mouse was separated into plasma and RBC fractions to measure the presence and clearance of tgPfHRP2 post-treatment by ELISA.
Curves were compared using a log-rank test (***p < 0.001; **p < 0.01; *p < 0.05). c Representative BinaxNOW Malaria RDTs demonstrating the
clearance time of tgPfHRP2 and Plasmodium aldolase from the whole blood of a PbPfHRP2 infected mouse that was administered artesunate and
pyronaridine to cure

Binding was defined as absorbance levels above those
measured for RBCs incubated with naïve plasma. While
protein levels quantified by ELISA were highly variable
in the RBC and plasma fractions within and across replicates, the average percent of total PfHRP2 protein bound
to uninfected, naïve mouse or human RBCs in vitro was
extremely low, measuring below 0.5% for all plasma/
serum samples tested (Additional file 5: Table S2).
Next, binding was investigated in vivo. BALB/c mice
(n = 3) were injected with 100,000 ng/mL of recombinant PfHRP2 (rPfHRP2) in order to achieve high plasma
protein levels and mimic plasma protein circulation and
elimination observed during severe malaria infections
(> 10% parasitaemia) [20, 27, 38]. ELISA was used to
quantify concentration and partitioning of rPfHRP2 in
the RBC and plasma fractions isolated from mice at regular intervals post-inoculation (Additional file 6: Table S3,
Additional file 7). At 0.5 h post-inoculation, the average
concentration of rPfHRP2 quantified in the plasma was
35,113 ng/mL (Additional file 7).
Minimal binding to uninfected RBCs was detected
within the first 12 h post-inoculation, on the order
of 3–13 ng/mL compared to the 900–35,000 ng/mL
of rPfHRP2 in the plasma at those same time points
(Additional file 6: Table S3). Consequently, the ratios
of rPfHRP2 in the uninfected RBCs compared to the

plasma in the first 12 h were extremely low, averaging
0.004 (Additional file 6: Table S3). The percent of the total
protein (RBC + plasma) that bound to the RBCs over
the time course was ≤ 1% (Additional file 6: Table S3).
No binding was detected in the naïve RBCs after 24 h,
despite plasma protein remaining detectable for a median
of 4 days post-inoculation (Additional file 7; Additional
file 6: Table S3). rPfHRP2 plasma clearance followed a
first-order decay process, with a very short calculated
plasma half-life of 1.9 h (median R
 2 = 0.998) (Additional
file 7).
Comparing parasite and tgPfHRP2 clearance in splenic
and asplenic mice

Because RBC pitting occurs in the spleen, how splenectomy in mice alters clearance, persistence, and
kinetics of tgPfHRP2 following infection with the PbPfHRP2 parasite and treatment with artesunate and
pyronaridine was investigated. The parasitaemia prior
to treatment (4–5 days post-infection) determined by
qPCR was significantly different between the splenic
(675,283 parasites/µL) and asplenic (1,429,170 parasites/µL) mice (Mann–Whitney U test, p = 0.041). To
normalize the data, the percent of total parasite DNA
remaining was calculated (Fig. 7a). On average, 71%
of total parasite DNA cleared on day 1 post-treatment
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Fig. 6 Investigation of PfHRP2 persistence in once-infected
RBCs post-treatment. a PbPfHRP2 iRBCs were isolated from mice
pre-treatment and once-infected RBCs were isolated on days 2, 3,
and 4 post-treatment with artesunate and pyronaridine. Uninfected
mouse RBCs were used as a control. b P. falciparum iRBCs were
collected from a patient pre-treatment. RBCs once-infected with P.
falciparum were isolated from the same human patient on days 2, 3,
and 12 post-treatment with artemether–lumefantrine. Uninfected
human RBCs were used as a control. Once-infected RBCs were
defined as cells with positive PfHRP2 staining (red) but no DAPI
staining (blue)

in splenic mice, but only 49% cleared in asplenic mice
(Fig. 7a). Additionally, in mice with intact spleens, all
parasite DNA cleared by day 7 post-treatment, but in
asplenic mice, DNA was detectable at very low levels
(≤ 1%) from days 12 to 14 post-treatment, leading to
a significantly longer overall clearance time of 13 days
(p = 0.0001, log-rank) (Fig. 7a, b). When measuring parasite clearance by microscopy, no differences between
splenic and asplenic mice were observed, as both demonstrated a median clearance time of 3 days.
In asplenic mice, the concentration of tgPfHRP2
was significantly higher in the RBCs compared to the
plasma over the days post-treatment (p = 0.005, random-effects GLS regression model) (Fig. 7c), which
was the same trend observed in splenic mice. tgPfHRP2
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elimination from the different blood fractions posttreatment also followed a first-order decay process
in the mice lacking spleens. In the asplenic mice, the
average tgPfHRP2 plasma half-life was 16.4 h (median
R2 = 0.990) and the average half-life in the RBCs was
not significantly different at 13.4 h (median R2 = 0.998)
(p = 1.00, Wilcoxon signed-rank test). The starting
tgPfHRP2 concentration in the RBC fraction of PbPfHRP2 infected mice prior to treatment was higher in
the splenic group (179,432.6 ng/mL) compared to the
asplenic group (144,806 ng/mL), despite a lower parasite load calculated by qPCR. Data was normalized
to percent of total tgPfHRP2 remaining in the RBCs
(Fig. 7d). Interestingly, when comparing percent of total
protein remaining in the RBCs post-treatment for the
splenic and asplenic mice, the initial tgPfHRP2 clearance rate for more than 99% of the protein was not different within the first 6 days post-treatment (Fig. 7d).
Consequently, the tgPfHRP2 RBC elimination halflives in splenic (13.1 h) and asplenic mice (13.4 h) were
not significantly different (p = 1.00, Mann–Whitney
U Test). However, lingering, low levels of tgPfHRP2
(< 1%) were detected in the RBCs of the asplenic mice
during days 10–14 post-treatment, leading to a significantly longer overall median clearance time of
13 days (p = 0.0009, log-rank) (Fig. 7d, e). This was not
observed in the splenic group, which had a median
clearance time of 9 days. As in splenic mice, tgPfHRP2
persisted significantly longer in the RBCs (11–14 days)
than the plasma (6–10 days) in asplenic mice (Fig. 7d).
One apparent difference between these groups was that
in asplenic mice, the tgPfHRP2 protein in the RBCs
cleared at the same time or before parasite genomic
DNA (Fig. 7b, e). In the splenic mice, at least a 1-day
difference in clearance time was observed (Fig. 5).

Discussion
Because PfHRP2 is expressed solely by P. falciparum,
previous experimentation to measure PfHRP2 kinetic
parameters have relied on in vitro culture and human
studies using mostly whole blood and occasionally
plasma [8–10, 39]. Here the compartmentalization of
PfHRP2 in the blood was explored in limited human
clinical samples and correlated some of the findings
in a novel transgenic P. berghei parasite (PbPfHRP2)
engineered to express PfHRP2 under the control of the
HSP70 promoter. Consistently higher levels of PfHRP2
in the RBC fraction compared to the plasma was demonstrated over the days post-treatment in both humans and
the transgenic PbPfHRP2 mouse model, which is consistent with data that previously demonstrated lower plasma
PfHRP2 levels compared to overall levels in the whole
blood post-treatment [10].
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Fig. 7 tgPfHRP2 protein kinetics following infection in splenectomized mice. Female BALB/c mice (n = 5) were splenectomized and infected
with the PbPfHRP2 parasite. Artesunate and pyronaridine were administered for cure. a, b Parasite genomic DNA clearance post-treatment was
quantified in the splenectomized mice using qPCR, with TaqMan primers and probes specific for P. berghei ANKA 18S rRNA, and compared to
parasite clearance time in mice with intact spleens (n = 7). Data were normalized by calculating percent of total parasite DNA remaining (a). Overall
clearance time for parasite DNA was compared in splenic and asplenic mice using a log-rank test (***p < 0.001; **p < 0.01, *p < 0.01) (b). Data are
represented as mean ± SEM. c Tail blood was extracted daily from splenectomized mice to quantify the concentration of tgPfHRP2 post-treatment
in the plasma and RBCs by ELISA. Data are represented as mean ± SEM. tgPfHRP2 levels post-treatment in the RBCs of both the splenic and asplenic
mice were compared. Data were normalized by calculating percent of total tgPfHRP2 remaining (d). Overall clearance time for RBC tgPfHRP2 was
compared in splenic and asplenic mice using a log-rank test (***p < 0.001; **p < 0.01, *p < 0.01) (e). Data are represented as mean ± SEM

There is recent evidence that persistence of the PfHRP2
antigen is due to the clearance of dying and non-viable
parasites by the process of erythrocyte pitting in the
spleen, in which the parasite is removed by splenic
macrophages from an intact RBC that then returns
to circulation as a once-infected RBC [10, 40]. These
once-infected RBCs have been identified and quantified previously by the presence of the P. falciparum
ring-infected erythrocyte surface antigen (RESA) using
flow cytometry and immunofluorescence microscopy
[10, 41]. RESA, like PfHRP2, is exported into the cytoplasm of the iRBC and associates with the iRBC membrane [42]. Recently, Ndour et al. also identified PfHRP2
in these once-infected RBCs isolated from P. falciparum patients 3 days post-artesunate treatment [10]. If
PfHRP2 is persisting within circulating once-infected
RBCs, this would predict slower protein clearance from
the RBC fraction of the blood compared to the plasma.
This was demonstrated in human patients treated with

either artemether–lumefantrine or atovaquone–proguanil. While the number of patients investigated was small,
it appears that this pitting phenomenon potentially not
only results from artesunate treatment and should be
further investigated in regards to treatment with other
anti-malarial regimens. In the transgenic mouse model
post-treatment with artesunate and pyronaridine, tgPfHRP2 also cleared more slowly from the RBCs than
plasma. Once-infected, PfHRP2 positive, parasite negative RBCs were abundantly detected post-treatment in
humans (at 0.1–1%) and were also observed in our mouse
model. The results confirm previous observations [10]
and suggest that these once-infected RBCs that remain
PfHRP2 positive and circulate in the peripheral blood
could be contributing to the long duration of RDT positivity despite the lack of an active infection. In the mouse
model, tgPfHRP2 persisted in the RBCs for at least
5–7 days beyond measurable peripheral blood parasitaemia by microscopy. However, tgPfHRP2 only persisted
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1 day post parasite genomic DNA clearance time as
measured by qPCR for the P. berghei ANKA 18S rRNA.
Because erythrocyte pitting is a method of parasite
removal in the spleen, the impact of splenectomy on the
in vivo tgPfHRP2 kinetics in the RBCs was investigated.
The spleen plays a central role in clearing parasites during infections with P. falciparum [43–45] and lethal
rodent malaria strains [46, 47]. It has been demonstrated
that in asplenic patients post-artesunate, treatment, parasite clearance was prolonged, though most parasites
appeared dead and were unable to be cultured ex vivo
[43, 48]. Consequently, the spleen is necessary for parasite clearance following the rapid anti-malarial activity
of artemisinin-based compounds [48]. In the transgenic
mouse model, we observed lingering, low levels of parasite DNA in the asplenic mice, leading to a longer overall
median clearance time of 13 days. This could suggest that
parasite DNA may persist after parasites are killed.
Supporting the hypothesis that erythrocyte pitting
depends on the spleen, once-infected, RESA positive
RBCs have not been observed in splenectomized patients
[43], nor were they observed in vitro, following artesunate treatment of P. falciparum culture [49]. While the
clearance of more than 99% of the tgPfHRP2 protein
from the RBC fraction was similar in splenic and asplenic
mice, there was a slower clearance of the remaining protein in asplenic mice. Parasite clearance mechanisms in
the absence of a spleen have not been extensively characterized, particularly in mice, but the liver along with
other lymphoid tissues may play a role [46]. One potential explanation could be that without the spleen to clear
parasites, slower parasite clearance overall could result in
prolonged detection of tgPfHRP2 in RBCs.
Additionally, PfHRP2 could be binding uninfected
RBCs in circulation upon its release from iRBCs, contributing to persistence. Little binding of PfHRP2 to
naïve RBCs was observed, as the percent of total protein bound was under 1–0.5% for all conditions tested.
Transmission electron microscopy images and protein
localization analysis from a previous study demonstrated
that PfHRP2 was localizing within the cytoplasm, immediately under the plasma membrane of P. falciparum
once-infected RBCs, further supporting the results [10].
Therefore, it seems binding of PfHRP2 to the surface of
uninfected RBCs is negligible and consequently not contributing to persistent antigenaemia.
One important difference observed between our novel
transgenic murine model and P. falciparum infection in
humans is the duration of PfHRP2 persistence after treatment. In mice infected with the transgenic PbPfHRP2, we
measured persistent antigenaemia for only 8–9 days following treatment, where PfHRP2 has been detected up
to 28–40 days following P. falciparum infections [11–13]
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and once-infected, PfHRP2 positive RBCs were observed
as long as 12 days post-treatment in our small human
study. These pitted, once-infected P. falciparum RBCs
have a shorter lifespan (7–28 days) than a naïve human
RBC (100–120 days) [10, 41]. Naïve murine RBCs only
have a lifespan of approximately 30–40 days [50, 51]. As
a result, pitted murine once-infected PbPfHRP2 RBCs
could have a shorter lifespan of only a few days, causing
shorter persistence duration. Additionally, shorter persistence duration could be due in part to the increased
pliability of P. berghei iRBCs [52], as erythrocyte pitting
seems to correlate with the increased rigidity of P. falciparum iRBCs [53]. Also unlike P. falciparum, P. berghei
preferentially infects reticulocytes [54], which differ from
mature RBCs and may not undergo pitting. The splenic
architecture of mice and humans differs [55–57], but
the ability of murine spleens to mechanically trap RBCs
with foreign/inclusion bodies and remove them through
a pitting-like mechanism has been demonstrated previously [58]. In fact, the number of Howell-Jolly inclusion
bodies increased from 2 to 3% in the peripheral blood of
mice following splenectomy [59]. Therefore, it is possible that the trapping and pitting mechanisms employed
in the mouse spleen are different from those in humans
and may be less sophisticated, leading to less pitting and
a shorter duration of PfHRP2 persistence in mice compared to humans. This could also explain the similar
kinetics observed for tgPfHRP2 post-treatment in the
RBC fractions of splenic and asplenic mice.

Conclusions
PfHRP2 persistence after treatment presents a critical challenge to diagnostic interpretation of the malaria
RDT, but the mechanism underlying this phenomenon
has not been extensively characterized. In this study, a
transgenic P. berghei parasite that expresses PfHRP2 was
generated and tgPfHRP2 kinetics was investigated in the
plasma and RBC fractions of the whole blood over time
post-treatment to correlate with human samples. Persistent PfHRP2 antigenaemia was observed for 8–9 days in
mice and appeared to be driven by a slower rate of elimination of PfHRP2 from the RBCs compared to plasma.
While the longevity of PfHRP2 antigenaemia in the transgenic mouse model was considerably shorter than what is
measured following a P. falciparum infection in humans,
once-infected RBCs that were positive for the PfHRP2
antigen were detected in mice. The fraction of these
once-infected RBCs present over the days post-treatment
was quantifiable in a small number of human patients
and detected these once-infected RBCs post-treatment
with artemether–lumefantrine and atovaquone–proguanil. While only 6 patients were investigated with most
timepoints within a few days, this data could indicate that
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pitting may not solely be driven by artesunate-based antimalarial regimens but could result from treatment with
a variety of anti-malarials, and thus should be further
explored. With the limited human samples included in
this study, the PfHRP2 half-life in humans was not estimated. It is important to note that time to clearance of
half of PfHRP2 is different than half of total time to clear
PfHRP2. Overall, these data suggest that erythrocyte pitting in the spleen could be driving persistent protein in
the RBCs and these once-infected RBCs are contributing
to a longer duration of RDT positivity for PfHRP2 following a successfully treated P. falciparum infection.

Additional files
Additional file 1: Table S1. Sequences of primers and fluorescent probes
used to quantify PbPfHRP2 and P. falciparum infections.
Additional file 2: Figure S1. PCR verification that transgenic PbPfHRP2
parasite carries the HRP2 gene. (A) PCR of 5′ and 3′ ends of the HRP2-2AGFP transgene from genomic DNA purified from whole blood from wildtype P. berghei ANKA (lane 1) or PbPfHRP2 infected Swiss Webster mice
(lane 2). (B) Integration PCR of genomic DNA purified from whole blood of
wild-type P. berghei ANKA (lane 1 and 3) or PbPfHRP2 infected Swiss Webster mice (lane 2 and 4). Lanes 1 and 2 show amplification upstream of the
5′ integration site of 230p (forward) and the end of plasmid GFP (reverse).
Lanes 3 and 4 show amplification at the start of the HRP2 gene (forward)
and after the 3′ integration site of 230p (reverse).
Additional file 3: Figure S2. Presence of once-infected RBCs post-treatment with different anti-malarials. Once-infected RBCs were detected in
a patient that was qPCR negative for Pfs25 on day 12 post-treatment with
artemether–lumefantrine (left) and another patient that was qPCR negative for Pfs25 on day 6 post-treatment with atovaquone–proguanil (right).
Once-infected RBCs were defined as cells with positive PfHRP2 staining
(red) but no DAPI staining.
Additional file 4: Figure S3. Investigation of the presence of onceinfected RBCs pre-treatment. iRBCs were isolated from a P. falciparum
infected patient with a parasitaemia of 2.9% quantified by blood film prior
to receiving treatment. No once-infected RBCs were observed prior to
treatment. iRBCs were defined as cells with positive PfHRP2 (red) and DAPI
staining (blue). Once-infected RBCs were defined as cells with positive
PfHRP2 staining (red) but no DAPI staining (blue).
Additional file 5: Table S2. Distribution of PfHRP2 between naïve human
or mouse RBCs and PfHRP2-containing plasma/sera incubated in vitro.
Additional file 6: Table S3. Distribution of rPfHRP2 between RBC and
plasma fractions isolated from mice (n = 3) post-recombinant protein
injection.
Additional file 7: Figure S4. Kinetics of recombinant PfHRP2 in plasma
following protein injection. Female BALB/c mice (n = 3) were injected
with rPfHRP2 protein. Plasma was collected at regular intervals post injection for quantification of rPfHRP2 plasma concentration. The protein halflife in each mouse was calculated and averaged using a first-order decay
equation model constrained at a plateau of Y = 0. Data are represented as
mean ± SEM.
Abbreviations
PfHRP2: P. falciparum histidine-rich protein II; RDT: rapid diagnostic test; RBC:
red blood cell; iRBC: infected red blood cell; PbPfHRP2: transgenic P. berghei
parasite engineered to express P. falciparum histidine-rich protein II; rPfHRP2:
recombinant P. falciparum histidine-rich protein II; tgPfHRP2: transgenic P.
falciparum histidine-rich protein II.
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